The Dilemma of Cure and Damage in Oligodendroglioma: Ways to Tip the Balance Away from the Damage

• Main Author: Ruurd Torensma
• Format: Article
• Language: English
• Published: MDPI AG 2018-11-01
• Series: Cancers
• Subjects: oligodendroglioma; single-cell RNA sequencing; pseudo-coloring MRI; Dendritic cell vaccination; fluorescence-guided surgery; mass spectrometry surgery; quality of life
• Online Access: https://www.mdpi.com/2072-6694/10/11/431

Current treatments for oligodendrogliomas are powerful but have a negative impact on the rest of the body. The bone marrow is damaged by the chemotherapeutics, but other parts of the body are also affected. In this paper, the current treatment method and its collateral damage is described. Therefore, therapies are needed that are more effective against the tumor while having less negative effects on the patient’s quality of life. Some potential therapies include optimal removal of the tumor by fluorescent-guided surgery (FGS), intraoperative desorption electrospray ionization-mass spectrometry (DESI-MS), better monitoring of the effects of therapy by pseudo-coloring shades of gray of MRI pictures, and using recent data from RNA sequencing of single cells and immunotherapy. These are all open new ways of treating this tumor. The RNA sequencing of single tumor cells unravels specific tumor antigens present in the differentiation status of the cancer cell. Stem cell antigens were expressed in dividing cells, while hypoxia inducible factor-α (HIF-1α) is expressed in all tumor cells. Cancer stem cell antigens can be loaded on dendritic cells to induce cytotoxic T-cells directed to cancer stem cells. These recent discoveries suggest a better quality of life with the same overall survival.